Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support ...

XI'AN CITY, SHAANXI PROVINCE, CHINA, January 21, 2026 /EINPresswire.com/ -- The global nootropics and wellness ...

Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment -- VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

XI'AN CITY, SHAANXI PROVINCE, CHINA, February 5, 2026 /EINPresswire.com/ -- The nutritional supplement industry is ...

Welcome to the Viking Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, February 11 ...

Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.

A comprehensive new market research report titled Industrial Silicones Market Size, Future Growth and Forecast 2033 reveals ...

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade ...

Investing.com -- Viking Therapeutics (NASDAQ:VKTX) stock surged 11.63% after the company announced plans to advance its experimental oral obesity drug VK2735 into late-stage trials in the third ...